IQVIA Holdings Inc. (NYSE:IQV) Stock Holdings Lessened by Kentucky Retirement Systems

Kentucky Retirement Systems lowered its stake in IQVIA Holdings Inc. (NYSE:IQV) by 0.9% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 13,730 shares of the medical research company’s stock after selling 130 shares during the period. Kentucky Retirement Systems’ holdings in IQVIA were worth $2,903,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Rise Advisors LLC bought a new position in shares of IQVIA in the first quarter valued at $31,000. Versant Capital Management Inc increased its holdings in shares of IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after buying an additional 110 shares in the last quarter. Riverview Trust Co acquired a new stake in IQVIA during the 1st quarter valued at $32,000. Opal Wealth Advisors LLC acquired a new stake in IQVIA during the 2nd quarter valued at $27,000. Finally, International Assets Investment Management LLC acquired a new stake in IQVIA during the 2nd quarter valued at $32,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Trading Up 0.8 %

Shares of NYSE:IQV opened at $244.62 on Friday. The stock has a market capitalization of $44.57 billion, a PE ratio of 33.42, a P/E/G ratio of 2.24 and a beta of 1.49. IQVIA Holdings Inc. has a 1 year low of $167.42 and a 1 year high of $261.73. The firm has a fifty day moving average price of $240.24 and a 200 day moving average price of $234.25. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The firm had revenue of $3.81 billion during the quarter, compared to analysts’ expectations of $3.79 billion. During the same period in the prior year, the company posted $2.22 earnings per share. IQVIA’s revenue for the quarter was up 2.3% on a year-over-year basis. Analysts expect that IQVIA Holdings Inc. will post 10.25 EPS for the current fiscal year.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Morgan Stanley boosted their target price on shares of IQVIA from $270.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday, July 23rd. Jefferies Financial Group downgraded shares of IQVIA from a “buy” rating to a “hold” rating and cut their target price for the company from $266.00 to $242.00 in a research note on Wednesday, July 24th. StockNews.com raised shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Thursday, September 5th. Argus raised shares of IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. Finally, UBS Group upped their price target on shares of IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $266.67.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.